NYSE - Nasdaq Real Time Price USD

Bausch + Lomb Corporation (BLCO)

Compare
18.90 +0.02 (+0.11%)
As of 10:51 AM EDT. Market Open.
Loading Chart for BLCO
DELL
  • Previous Close 18.88
  • Open 19.01
  • Bid 18.83 x 1100
  • Ask 18.88 x 900
  • Day's Range 18.83 - 19.00
  • 52 Week Range 13.16 - 21.00
  • Volume 23,805
  • Avg. Volume 763,553
  • Market Cap (intraday) 6.677B
  • Beta (5Y Monthly) 0.48
  • PE Ratio (TTM) --
  • EPS (TTM) -1.29
  • Earnings Date Jul 31, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 27.01

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

www.bausch.com

13,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BLCO

View More

Performance Overview: BLCO

Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BLCO
10.79%
S&P/TSX Composite index
15.09%

1-Year Return

BLCO
16.09%
S&P/TSX Composite index
26.81%

3-Year Return

BLCO
2.16%
S&P/TSX Composite index
16.90%

5-Year Return

BLCO
2.16%
S&P/TSX Composite index
16.90%

Compare To: BLCO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BLCO

View More

Valuation Measures

Annual
As of 10/3/2024
  • Market Cap

    6.67B

  • Enterprise Value

    11.02B

  • Trailing P/E

    --

  • Forward P/E

    26.18

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.47

  • Price/Book (mrq)

    1.02

  • Enterprise Value/Revenue

    2.45

  • Enterprise Value/EBITDA

    20.55

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -10.15%

  • Return on Assets (ttm)

    0.96%

  • Return on Equity (ttm)

    -6.49%

  • Revenue (ttm)

    4.5B

  • Net Income Avi to Common (ttm)

    -456M

  • Diluted EPS (ttm)

    -1.29

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    285M

  • Total Debt/Equity (mrq)

    70.39%

  • Levered Free Cash Flow (ttm)

    -88.88M

Research Analysis: BLCO

View More

Company Insights: BLCO

Research Reports: BLCO

View More

People Also Watch